Summary
Forty-six patients with acute leukemia were treated with mitoxantrone as a single agent. Twenty-nine patients had relapsed and/or refractory acute leukemia. Seventeen patients with acute non-lymphatic leukemia had received no prior treatment. Twelve mg/m2 of mitoxantrone was given intravenous on five consecutive days. Treatment related side effects included bone marrow suppression, mucositis, alopecia, nausea, vomiting and infection. Cardiotoxicity was documented in 7 patients. This study reconfirms that mitoxantrone is an active agent in acute leukemia with complete response documented in 10 of 29 patients with relapsed and/or refractory acute leukemia (34% response rate, 95% confidence limits 18–53%) and complete response documented in 11 of 17 patients (65% response rate, 95% confidence limits 38–87%) with previously untreated acute non-lymphatic leukemia.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Zee-Cheng RKY, Cheng CC: Antineoplastic agents. Structure-activity relationship study of bis (substituted aminoalkylamino) anthraquinones. J Med Chem 21:291–294, 1978
Cheng CC, Zbinden G, Zee-Cheng RKY: Comparison of antineoplastic activity of aminoethylaminoanthraquinones and anthracycline antibiotics. J Pharm Sci 68:393–396, 1979
Johnson RK, Zee-Cheng RKY, Lee WW, Acton EM, Henry DW, Cheng CC: Experimental antitumor activity of aminoanthraquinones. Cancer Treat Rep 63:425–439, 1979
Wallace RE, Murdock KL, Angier RB, Durr FE: Activity of a novel anthracenedione, 1,4-dihydroxy-5,8-bis-[((2((2-hydroxyethyl)amino)ethyl)amino)]-9,10-anthracenedione dihydrochloride, against experimental tumors in mice. Cancer Res 39:1570–1574, 1979
Paciucci PA, Ohruma T, Cuttner J, Silver RT, Holland JF: Mitoxantrone in patients with acute leukemia in relapse. Cancer Res 43:3919–3922, 1983
Estey EH, Keating MH, McCreadie KB, Bodey GP, Freireich EJ: Phase II trial of mitoxantrone in refractory acute leukemia. Cancer Treat Rep 67:389–390, 1983
Prentice HG, Robbins G, Ma DDF, Ho AD: Mitoxantrone in relapsed and refractory acute leukemia. Semin Oncol 11:32–35, 1984
Paciucci PA, Cuttner J, Holland JF: Mitoxantrone as a single agent and in combination chemotherapy in patients with refractory acute leukemia. Semin Oncol 11:36–40, 1984
Moore JO, Olsen GA: Mitoxantrone in the treatment of relapsed and refractory acute leukemia. Semin Oncol 11:41–46, 1984
Meyer P, Ho AD, Ehninger G, Mjaaland I, Heidemann E, Seither E: Mitoxantrone in the treatment of relapsed and refractory acute leukemia. Invest New Drugs 3:203–206, 1985
Van Echo DA, Shulman PN, Ferrari A, Budman D, Markus SD, Wiernik PH: A Phase II trial of mitoxantrone (DHAD; NSC 301739) in adult acute leukemia. Amer Soc Clin Oncol (Abstr) 1:132, 1982
Prentice HG, Robbins G, Ma DDF, Ho AD: Sequential studies on the role of mitoxantrone in the treatment of acute leukemia. Cancer Treat Rev 10:57–63, 1983
Masaoka T, Shisata H, Oguma S, Nagai K, Kitani T, Horiuchi A, Yasunaga K, Yonezawa T, Kawagoe H: A phase II study of mitoxantrone in acute leukemia. Invest New Drugs 3:197–201, 1985
Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649–655, 1982
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Vorobiof, D.A., Falkson, G., Coccia-Portugal, M.A. et al. Mitoxantrone in the treatment of acute leukemia. Invest New Drugs 5, 383–388 (1987). https://doi.org/10.1007/BF00169980
Issue Date:
DOI: https://doi.org/10.1007/BF00169980